Hims & Hers Health Inc(HIMS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:51 AM ET (Korea 9/11 20:51)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.62 | Insider Own | 9.21% | Shs Outstand | 224.9M | Perf Week | -4.32% |
| Market Cap | 6.40B | Forward P/E | 90.5 | EPS next Y | 152.51% | Insider Trans | -1.78% | Shs Float | 211.8M | Perf Month | -10.06% |
| Enterprise Value | 7.11B | PEG | 7.57 | EPS next Q | 0.06 | Inst Own | 67.16% | Short Float | 27.7% | Perf Quarter | -1.22% |
| Income | -0.14B | P/S | 2.48 | EPS this Y | -213.23% | Inst Trans | 2.05% | Short Ratio | 4.01 | Perf Half Y | 6.03% |
| Sales | 2.58B | P/B | 19.75 | EPS next 5Y | 11.96% | ROA | -5.16% | Short Interest | 58.67M | Perf YTD | -15.49% |
| Book/sh | 1.39 | P/C | 7.61 | EPS past 3/5Y | - | ROE | -32.03% | 52W High | -57.98% ($65.30) | Perf Year | -42.57% |
| Cash/sh | 3.6 | P/FCF | 99 | Sales past 3/5Y | 64.55% 73.63% | ROIC | -7.64% | 52W Low | 99.71% ($13.74) | Perf 3Y | 320.21% |
| Dividend Est. | - | EV/EBITDA | 82.21 | EPS Y/Y TTM | -169.91% | Gross Margin | 54.19% | Volatility(W/M) | 3.69% 6.23% | Perf 5Y | 215.04% |
| Dividend TTM | - | EV/Sales | 2.76 | Sales Y/Y TTM | 28.04% | Oper. Margin | -0.03% | ATR (14) | 1.81 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.87 | EPS Q/Q | -320.75% | Profit Margin | -5.51% | RSI (14) | 42.81 | Recom | 2.53 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.93 | Sales Q/Q | 38.25% | SMA20 | -6.75% ($29.43) | Beta | 2.44 | Target Price | $32.22 |
| Payout | - | Debt/Eq | 4.77 | Earnings | 2026/8/10 | SMA50 | -12.16% ($31.24) | Rel Volume | 0.52 | Prev Close | $27.9 |
| Employees | 2442 | LT Debt/Eq | 4.74 | EPS/Sales Surpr. | -642.97% 7.77% | SMA200 | -2.93% ($28.27) | Avg Volume(3M) | 14.62M | Price | $27.44 |
| IPO | 2019/9/13 | Option/Short | Yes/Yes | Trades | 36983 | Volume | 7,536,847 | Change | -1.65% |
Company
HIMS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. healthcare company that operates a consumer-direct (D2C) telehealth platform. It connects patients with online consultations and prescriptions, offering personalized treatments and subscription-based products in areas such as hair loss, sexual health, weight loss, mental health, and skincare. Its performance is tied to subscriber numbers, average revenue per user, and the regulatory environment, making it a healthcare stock sensitive to those factors.
Over the past 1 year, roughly in the middle
58% below its 1-year high.
HIMS has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -213.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by +320.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 67.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ULTI 0.05%
HEAL 0.04%
EKG 0.03%
IBUY 0.03%
BUZZ 0.03%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
HIMZ 60M
HIYY 14M
HIMC -
HMYY -It ranks #4 in the industry
Based on market cap of $6B.
HIMS $6B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is HIMS?
HIMS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of HIMS?
The market cap of HIMS is approximately $6.4B, ranking 1,202 within its sector.
What is the 52-week high and low for HIMS?
HIMS has recorded a 52-week high of $65.30 and a low of $13.74.
